With ageing of their populations, many societies are challenged with serious systemic diseases. One of the causes of these diseases could be the age-related defects in immune system termed immunosenescence. Immunosenescence is characterized by accumulation of memory and non-functional immune cells, impaired signalling due to restricted repertoire of receptors, overall pro-infl ammatory environment and complete dysregulation of the immune system. Consequences of immunosenescence are serious, older people are not able to respond to new stimuli, including infections and vaccinations and are more prone to oncologic, neurodegenerative and autoimmune diseases (Ref. 49). Text in PDF www.elis.sk.
Immunosenescence and its hallmarks
Immunosenescence is a process during which the functions of the immune system decline with age. The consequences of immunosenescence are serious-elderly people are not able to respond properly to new infections and the balance between production of pro-and anti-infl ammatory cytokines is shifted to pro-infl ammatory phenotype. Aged immune cells are producers of a large number of specifi c factors, including proteases (metalloproteases MMP-1, 3, 10), chemokines (C-X-C motif chemokine ligand 1-CXCL1, IL-8, C-C motif chemokine ligand 2-CCL2), cytokines (IL-1, IL-6, IL-7) and many others (1) . On one hand these factors can activate the cellular immunity (2) , but on the other hand, the presence of these factors leads to functional changes in surrounding tissues caused by increased autoimmune reactions and induces the systemic pro-infl ammatory or even hyper-infl ammatory phenotype which is associated with high mortality risk (3, 4) .
The causes of immunosenescence are multiple and not completely understood. The problem is that immunosenescence affects the immune system on every level and both, innate and acquired immunity. The T-cell compartment exhibits consistent and pronounced age-related changes. These include thymus involution and decreased production of naive T cells (CD45RA+ CD62L+, CD95+) in the periphery (5), loss of costimulatory protein CD28 and differentiation to effector phenotype. Moreover, diminished responsiveness to TCR signalling culminates in blunted T-cell proliferation, reduced IL-2 production and effector T-cell differentiation, lowering or inversion of CD4: CD8 T-cell ratios, reduction in naive and increase in memory cells, telomere shortening, and Tcell receptor (TCR) repertoire reduction (6) . Additionally, analysis of the sera from elderly showed elevated C-reactive protein and transthyretin (7) . It was shown that the occurrence of T-cell clonal expansions (TCE) in mice and humans is an age-dependent phenomenon, associated with dramatic losses in the TCR repertoire. Consistent with all of the above changes, there is some evidence that impaired CD8 response to virus infections in mice may partially correlate with age-related TCR repertoire loss (8, 9) . Some studies showed that upregulation of several cytokines (i.e. TNF-α) induced CD28 downregulation (10, 11) . It seems that CD28-cells occur in pro-infl ammatory environment and in turn, they produce more pro-infl ammatory cytokines and thus they support the development of pro-infl ammatory phenotype in elderly. Other studies pointed to the changes in number of CD4+CD25+ regulatory T cells, which are elevated in older age, but their suppressive activity to cytotoxic T cells and NK cells is decreased (12, 13, 14) .
Howe ver, T cells are not the only ones affected by immunosenescence. Changes on B cells (CD3-CD19+) and NK cells (CD3-CD16+CD56+) were recorded as well. In ageing population of NK cells, upregulation of CD57 was detected and thus CD57 was defi ned as a marker for maturation of NK cells and for cytotoxicity (15, 16, 17, 18) . Changes in the expression of CD57 during ageing are prominent on cytotoxic T cells and thus CD57 was recognized as a marker of immune senescence (19) . Several studies showed that under conditions of long-term stimulation, cytotoxic T cells change their phenotype from CD28+CD57-to CD28-CD57+ (20) . These CD57+ cells show basic characteristics of senescence such as short telomeres, low telomerase activity, low expression of cell-cycle associated genes and a limited proliferative capacity (20; 15) . The cells were able to proliferate in a specifi c cytokine environment, were highly cytotoxic (21, 22) , they expressed NK receptors and thus acquired NK-like phenotype (17, 18) , but their apoptotic properties were questioned (16, 23) .
The production of naive B cells declines with age and memory B cells and plasma cells of limited specifi cities accumulate, which contributes to the decrease in the capacity to respond to new antigens (24, 25, 26, 27, 28) . Age-related changes in the bone marrow, including the accumulation of fat deposits, are associated with the potential loss of specialized survival niches and a decrease in the number of B-cell progenitors. Although aged organisms have normal numbers of B cells in the periphery, they manifest several changes in their antibody repertoire, including a shift in antibody production from IgG to IgM, from high affi nity to low affi nity, and from specifi city for foreign antigens to specifi city for self-antigens (24, 25) .
Functional changes associated with increasing age are also present on dendritic cells and monocytes. Data are not complete for this part of immune system yet, but it seems that aged antigen presenting cells have impaired endocytosis and chemotaxis, downregulated expression of costimulatory molecules (CD86), decreased ability to present an antigen and lowered production of IL-12, which is important for T cells proliferation (29, 30, 31) .
Neurodegeneration and the immune system
Alzheimer´s disease is a complex disorder characterized by the presence of amyloid plaques and neurofi brilary tangles in brain and the formation of these pathological hallmarks is driven by different mechanisms. Amyloid beta and pathological tau proteins seriously affect the state of the immune system in the brain and in the periphery. In order to reveal the molecular underpinnings of the interaction of pathologically modifi ed tau proteins and the immune system, it is necessary to use transgenic models of neurofi brillary pathology with precisely staged and predictable progression of neurofi brillary pathology.
There is a massive over-activation of the immune cells in neurodegenerative disorders, like Alzheimer´s disease (AD), which results in neuroinfl ammation. Over-activated microglia form clusters around amyloid plaques, which are one of the main pathological hallmarks of Alzheimer´s disease (32) . In vitro studies showed that microglia can phagocytize amyloid beta, but they are not able to degrade it (33, 34) . Other results showed that not only amyloid beta, but also pathologically modifi ed tau protein is a cause of neuroinfl ammation in Alzheimer´s disease affected brain. Expression of a pathological form of tau protein in animal models leads to a prominent activation of microglia and astrocytes and to infi ltration of leukocytes (mainly monocytes and dendritic cells) from periphery to the site of pathology (35, 36) .
Moreover, the nature of immune response in the brain is heavily affected by the genetic background of the transgenic animals (36) and thus it can be supposed that the genetic factors can infl uence the nature of the immune response in Alzheimer´s disease patients. Prominent differences were identifi ed in the individual components of the peripheral immune system of AD patients. The major changes included altered distribution and activity of lymphocytes and macrophages, the presence of autoantibodies and abnormal cytokine production or even elevated numbers of T cells in the brains of the patients (37) . Other studies showed lowered numbers of T and B cells in blood of AD patients, although the numbers of NK cells remained unaltered (38) . Additionally, differences were described in cell counts in individual subpopulations of T cells. The numbers of cytotoxic T cells were lower and the numbers of helper T cells were higher in AD patients (38, 39) . However, there was no correlation between the cognitive decline and T cell profi le (38) . Another study, which involved larger group of AD patients with various degrees of neurodegeneration, showed signifi cant reduction of B cell numbers (40) . On the other hand, there were no differences in the total numbers of T cells and NK cells, only specifi c subpopulations of cytotoxic T cells expressing CD71 and CD28 were elevated. All these changes in lymphocytes distribution and the selective elevation of some subpopulations of T cells in AD patients suggest that AD neurodegeneration processes have signifi cant impact on the peripheral immune system. In vitro studies of monocytes and macrophages isolated from blood of AD patients showed a prominent pro-infl ammatory phenotype and the cells produced much higher amounts of pro-infl ammatory cytokines compared to cells from healthy controls (41) . On the other hand, these cells are less effective in phagocytosis of amyloid-beta and showed limited potential for differentiation to macrophage phenotype (42) .
Vaccination and immunosenescence in neurodegeneration
Immunosenescence is generally associated with higher risk of osteoporosis, Alzheimer´s disease, cancers and various autoimmune disorders (43) . Immunosenescence is a serious problem for public health, since elderly are on one hand more prone to common infections, but on the other most of them are not able to respond properly to common vaccinations. Only 17-53 % of elderly can produce specifi c antibodies in response to vaccination, in contrast to 70-90 % of young adults (44) . Insuffi cient immune response is most prominently found in infl uenza vaccination programs but can heavily affect the development of other vaccines intended for elderly, such as vaccines against Alzheimer´s disease. Current data suggest that the low response to vaccination against infl uenza is associated with expansion of cytotoxic T cells without expression of CD28 costimulatory molecule (45, 46, 47) . A similar situation was found in HIV patients, which exhibit high percentage of cytotoxic T cells without CD28 marker and with shortened telomeres.
In a study dealing with the clinical trial of the vaccine against Alzheimer´s disease, it was showed that the titres of vaccine-specifi c antibodies strongly correlate with the relative numbers of T lymphocytes, especially T h lymphocytes (48) . The vaccine was able to induce antibody immune response and interfere with the progress of the disease despite the neurodegenerative changes in the brains of the experimental animals (49) . The question still remains, in what stage of neurodegeneration immune system fails in recognition of the new stimuli and protection against the disease.
All these data suggest that the identifi cation of new, reliable T-and B-cell markers of immunosenescence and neurodegeneration can bring in a new insight into the ageing immune system affected by neurodegeneration (e.g. Alzheimer´s disease) and can help to predict the responsiveness of the immune system to new therapeutic antigens.
Conclusion
Immunosenescence is becoming one of the civilisation diseases, interfering with all the biggest problems in current medicine. From the scientifi c point of view, the causes and mechanisms of immunosenescence are mostly unknown. The papers published on the topic are rather descriptive, focusing on individual markers or individual pathways. For better understanding of the immune system and immunosenescence, more holistic approach and new multi-parameter methods combined with bioinformatics will be needed. This could be the way to fi ght new infections, to design potent vaccination programs for elderly and to develop new therapeutic vaccines that are effective at any age.
